UCB SA (OTCMKTS:UCBJF) Short Interest Down 63.1% in April

UCB SA (OTCMKTS:UCBJF) was the recipient of a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 215,500 shares, a drop of 63.1% from the March 31st total of 584,000 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average trading volume of 200 shares, the short-interest ratio is presently 1,077.5 days.

UCB Price Performance

Shares of UCB stock opened at $150.70 on Tuesday. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The business has a 50-day moving average price of $176.23 and a two-hundred day moving average price of $183.04. UCB has a 1-year low of $126.05 and a 1-year high of $209.66.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.